This article examines the evolving exit landscape for PE investors in India, the key regulatory and structural issues that should be addressed well before an exit process is launched, and the practical considerations that can affect deal certainty across the principal exit routes available to investors.
The article discusses the regulatory and compliance risks faced by Global Capability Centers (GCCs) and emphasizes the importance of embedding governance, compliance, and risk management into their operating model from the outset.
The article discusses the principal legal and practical considerations that foreign stakeholders should keep in mind when establishing or scaling a GCC in India.
The article discusses the Bombay High Court’s decision in Blue Cross Laboratories Pvt. Ltd. v. Alto Healthcare Pvt. Ltd., where the Court held that the mark ‘MEFIAL-SPAS’ infringed Blue Cross’s registered pharmaceutical mark ‘MEFTAL-SPAS’. It emphasized that even minor spelling changes can cause deceptive similarity in pharmaceutical products, where confusion may affect public health. The Court also found infringement of copyright and trade dress due to imitation of packaging, colour scheme, and artwork. According to the authors, commercial courts are becoming increasingly ready to make a considerable effort to punish those infringers who act deliberately, fraudulently, and opportunistically.
The article examines how the amendment by the Finance Act, 2026 in the Income-tax Act, 2025 changes the consequences for not-for-profit organisations (‘NPOs’) pursuing general public utility objects. The 2026 amendment removes many breaches from the ‘specified violations’, thus reducing the risk of cancellation. The authors however note that non-compliance may still lead to denial of exemption, taxation of commercial income, and scrutiny of charitable purpose. According to them, the change offers operational flexibility while preserving discipline governing NPOs.
Article 3 of the WTO SCM Agreement provides for two types of subsidies which are considered as prohibited subsidies, namely (i) export contingent and (ii) import substitution.
At times an applicant, i.e., a company or an individual may decide to file a patent application directly in a foreign country or as an international application under PCT other than in India, without first filing a patent application in India due to various reasons.
By Vidushpat Singhania Protection of database and associated rights is gaining traction in India. The vast volume and deluge of data available with the Business Processing Offices in India from jurisd
By Bhargav Mansatta After much furore over opening up of the retail sector to foreign investment, Government of India (GOI) announced its decision to allow FDI upto 51% in multi-brand retail trading u
By Surbhi Premi In 1997, the Government of India introduced the Voluntary Disclosure of Income and Wealth Scheme, 1997 (VDIS), an amnesty scheme under the direct taxes which unearthed approximately Rs
The rules of the Bar Council of India prohibit law firms from advertising and soliciting work through communication in the public domain. This website is meant solely for the purpose of information and not for the purpose of advertising. Lakshmikumaran & Sridharan does not intend to solicit clients through this website. We do not take responsibility for decisions taken by the reader based solely on the information provided in the website. By clicking on 'ACCEPT', the visitor acknowledges that the information provided in the website (a) does not amount to advertising or solicitation and (b) is meant only for his/her understanding about our activities and who we are.
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy.